17 Aug 2012
(MENAFN) Jordan-based drugmaker Hikma Pharmaceuticals posted a 34.8 percent increase in half-yearly profits, Gulf Business reported.
The company said it made USD532.3 million during the first half of 2012 year-on year, while operating profit rose 53.1 percent increase to USD75.1 million.
Generics revenue declined by 27.0 percent to USD55.8 million, as a result of the impact of additional compliance work at the Eatontown facility and increased pricing pressure.
Injectables revenue grew 94 percent, offsetting lower margins in the generics business.
The company revised its full year revenue outlook guidance to around USD115 million.
Hikma launched 37 products and received 33 product approvals in the first half of this year.
08 Apr 2026
BBK awards over BD 1 Million to 273 winners in the February Al Hayrat Grand Prizes draw
01 Mar 2026
BBK activates partial remote working system for its workforce to ensure employee and customer safety and service continuity
24 Feb 2026
BBK discloses its financial results for the year ended 31st December 2025
05 Feb 2026
BBK announces December Al Hayrat Grand Prize winners and another wave of Grand prizes for February
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more